Sign in Subscribe
Pharmaceutical industry

Novavax's Novasome Vaccine Clears FDA for Human Trials

Strategic Insights

— 1 min read

Novavax Inc.'s experimental vaccine against Shigella flexneri 2a, a bacterium that causes gastrointestinal infections worldwide, has been cleared for human testing by the US Food and Drug Administration (FDA). The novel vaccine, known as Novasome, is a lipid vesicle-based oral vaccine that has shown promising results in animal trials, producing antibodies against the endotoxin component of the bacterium.

The FDA's authorization marks a significant milestone for Novavax and its partner, IGI Inc., which will conduct Phase I human clinical trials. The trials will assess the vaccine's safety and efficacy in human subjects. Shigella flexneri 2a is a significant public health concern, causing up to 25% of all Shigella infections in the United States, primarily through food and water transmission.

Key Takeaways:

  • Novavax's Novasome vaccine has been approved by the FDA for Phase I human clinical trials, marking a significant step forward in the development of a vaccine against Shigella flexneri 2a.
  • The vaccine, which is orally administered, has shown promising results in animal trials, producing antibodies against the endotoxin component of the bacterium.
  • Shigella flexneri 2a is a highly infectious bacterium that causes diarrhea and dehydration, and is transmitted through human-to-human contact, primarily through food and water.
  • The organism is implicated in up to 25% of all Shigella infections in the United States.
  • The vaccine's development is a collaborative effort between Novavax and IGI Inc.
  • The regulatory process is a lengthy one, and it cannot be predicted when or if a license to sell the vaccine might be issued.

Statistics:

  • 25%: The percentage of all Shigella infections in the United States that are attributed to Shigella flexneri 2a (Source: [1]).
  • Shigella flexneri 2a is a significant public health concern, causing a substantial number of gastrointestinal infections worldwide.
  • The vaccine is orally administered, making it a potential game-changer in the prevention of Shigella infections.
  • The Phase I clinical trials will assess the vaccine's safety and efficacy in human subjects.

Sources:

[1] PRNewswire, "Novavax Inc. Authorizes Phase I Human Clinical Testing of Novasome Vaccine Against Shigella flexneri 2a" (May 22, 1995).

Read more